Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma

Christine H. Chung, Paula R. Pohlmann, MacE L. Rothenberg, Brian B. Burkey, Joel Parker, Kevin Palka, Joseph Aulino, Igor Puzanov, Barbara Murphy

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]). Methods The clinical information was collected by a retrospective medical record review under an Institutional Review Board-approved protocol. From 4 tumors and 2 normal mucosal epithelia, global gene expression, and IGF-1R and dihydrofolate reductase (DHFR) protein levels were determined. Results Effective target inhibition in the tumor was confirmed by the decreased protein levels of total and phospho-IGF-1R after treatment with AMG-479. Decreased level of DHFR and conversion of a gene expression profile associated with cetuximab-resistance to cetuximab-sensitivity were also observed. Conclusion This suggests that the combination of AMG-479 and MTX or cetuximab may be a promising therapeutic approach in refractory HNSCC.

Original languageEnglish (US)
Pages (from-to)1804-1808
Number of pages5
JournalHead and Neck
Volume33
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Keywords

  • AMG-479
  • cetuximab
  • head and neck squamous cell carcinoma
  • IGF-1R inhibitor
  • methotrexate

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this